Search for drugs:
Typing the drug name to query
BARICITINIB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effect of trabectedin on the QT/QTc interval was evaluated in 75 patients who received placebo on day 1 and trabectedin (1.3 mg/m2) as a 3-hour intravenous infusion on day 2. No patients in the study showed a QTc interval exceeding 500 msec or more than 60 msec increase from baseline, and no large changes in the mean QTc interval (i.e., >20 msec) were observed.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
3655
38377932
Odds Ratio = 0.436
Drug Property Information
ATC Code(s):
- L04AA37 - baricitinib
- L04AA - Selective immunosuppressants
- L04A - IMMUNOSUPPRESSANTS
- L04 - IMMUNOSUPPRESSANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:baricitinib
Active Ingredient UNII:ISP4442I3Y
Drugbank ID:DB11817
PubChem Compound:44205240
CTD ID: C000596027
CAS Number:1187594-09-7
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 4.0 mg/day L04AA37
Chemical Structure: 
SMILE Code:
CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Reference
1: Pharmacogenomics of COVID-19 therapies.
[Takahashi Takuto,Luzum Jasmine A,Nicol Melanie R,Jacobson Pamala A]NPJ Genom Med,2020 Aug 18;5:35. PMID: 32864162
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.